BIOTECH FRANCE |
|
| Quick Click ! | Monthly news | Home-Site | Faqs | Legends | Search | Companies | Events | Environment | Home-Biotech |
|---|
|
|
|
|
|
AbAg | Abcys | Affichem | AgateBioservices | AisaTherapeutics | AliX | Alphelys | Ambiotis | AnacondaPharma | ArianaPharmaceuticals | AtlanticBoneScreen | AureusPharma | BioAlliancePharma | Biocortech | BioCydex | BioMedicalDiagnostics | Biomethodes | Biomup | BioProteinTechnologies | BioSystemsInternational | BMSystems | BTPharma | Cellectis | CellialTechnologies | CellVax | CellVir | CerenisTherapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytomics | DBVTechnologies | Diatos | DNATherapeutics | DrugabuseSciences | Dynabio | EndotisPharma | Epixis | ERYtechPharma | Exonhit | FaustPharmaceuticals | FlamelTechnologies | Fluofarma | FoveaPharmaceuticals | GemacBio | Genepep | Genewave | Genfit | GenOdyssee | GenoSafe | GenoSciencePharma | Genoscreen | GenOway | HeliosBiosciences | Hybrigenics | HyphenBioMed | Imagene | ImmunId | Immutep | Imstar | InCellArt | IndiciaBiotechnology | InnatePharma | IntegraGen | Ipsogen | Ivagen | LibraGen | Mapreg | MATBiopharma | MedesisPharma | Mellitech | MeristemTherapeutics | MicroBioChips | MilleGen | MitoProd | Murigenetics | Mutabilis | Myosix | NanoBiotix | NautilusBiotech | Neorphys | Neovacs | Neuronax | NicOx | Nokad | Novagali | Novexel | NovoCIB | Novotec | ObeTherapy | Oligovax | Oncodesign | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | PherecydesPharma | PraXcell | Proteogenix | Proteus | QuantumGenomics | SepalPharma | SerialGenetics | ShigaMediX | SiseneBiotechnologies | SkuldTech | Synapcell | Synprosis | TcLandExpression | Theraptosis | TheraVectys | Transat | Transgene | Trophos | TxCell | UroGene | UROsphere | Urrma | VaxonBiotech | Vectalys | VigiCell | Vivalis | XenTech |
| COMPANY | YEAR | LOCATION | BUSINESS MODEL | MANAGEMENT | TOT-M€ | LAST-M€ | FOCUS | STAGE |
|---|---|---|---|---|---|---|---|---|
| AbAg Profile + www.no-website.net | 2001 | IDF Chilly-Mazarin (near Paris) | Design, Diagnostics Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine Clients: Pharmaceutical industry | Start-up | Managing Dir.: Bourlioux (Marc) [co-founder, born 1963] Sc.Dir.: Fin.Dir.: BusDev: Financers: Innoven Partners, Société Générale A.M. | 8.0 | 6.0 | Infections | Preclin |
| Abcys Profile + www.abcysonline.com | 1999 | IDF Paris | Design, Reagents Key words: Immunology, Cytokines, Cell culture, Stem cells, Production, Distribution, Third Parties Clients: Research institutes, Hospitals, Universities, Pharmaceutical industry research labs, Diagnostic industry | Start-up | Managing Dir.: Martin (Thierry) [born 1961] Sc.Dir.: Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Cell | Trade |
| Affichem Profile + www.affichem.com | 2002 | Midi-Pyrénées Toulouse | Design, Drugs (also Design, Diagnostics) Key words: Proteins, Dendrogenins, Cancer, Degenerative diseases Clients: Prescribers | Start-up | Managing Dir.: Silvente (Stéphane) [co-founder, born 1968] Sc.Dir.: Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Cancers | Preclin |
| Agate Bioservices Profile + www.agatebioservices.com | 2005 | PACA Alès | Contract, Services Key words: Gene expression, Protein production, Gene delivery, Insect cells expression, Baculovirus Clients: Pharmaceutical industry, Biotech, Research labs | Personal venture | Managing Dir.: Chaabihi (Hassan) [founder, born 1962, Ph.D.] Sc.Dir.: Chaabihi (Hassan) Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.008 M€) | n.a. | n.a. | Target | Preclin |
| Aisa Therapeutics Profile + www.no-website.net | 2005 | IDF Évry (near Paris) | Discovery, Drugs Key words: Inflammation Clients: | Personal venture | Managing Dir.: d'Alessio (Patrizia) [founder, born 1952, M.D., ex-Inserm] Sc.Dir.: Fin.Dir.: BusDev: Financers: Critt Chimie, Anvar | n.a. | n.a. | Inflammation | Incub |
| AliX Profile + www.alix-pharma.com | 2002 | Alsace Strasbourg-Illkirch | Discovery, Drugs (also Design, Protein) Key words: Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage Clients: Research labs | Spin-off | Managing Dir.: Renaud (Jean-Paul) [founder, born 1960, Ph.D., ENSCP, ex-CNRS] Sc.Dir.: Renaud (Jean-Paul) Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.07 M€) | n.a. | n.a. | Multiple | Preclin |
| Alphelys Profile + www.alphelys.com | 2001 | IDF Plaisir (near Paris) | Design, Solutions Key words: Instruments, Tissue array, Molecular histology, Imaging, Software, Reagents Clients: Pharmaceutical industry, Research labs | Personal venture | Managing Dir.: Chaumat (Pierre) [founder, born 1965] Sc.Dir.: Fin.Dir.: BusDev: Financers: none (100% privately owned, capital 2007 = 0.04 M€, 2006 = 0.11 M€) | 0.4 | n.a. | Multiple | Preclin |
| Ambiotis Profile + www.no-website.net | 2007 | Midi-Pyrénées Toulouse | Contract, Services Key words: Validation, Anti-inflammatory Clients: Pharmaceutical industry, Cosmetics, Agro-food | Personal venture | Managing Dir.: Dubourdeau (Marc) [founder, born 1973, M.D., Ph.D. Immunology, Ms. Management (Toulouse)] Sc.Dir.: Fin.Dir.: BusDev: Financers: privately owned (capital 2007 = 0.04 M€) | n.a. | n.a. | Inflammation | Subcontractor |
| Anaconda Pharma Profile + www.anacondapharma.com | 2003 | IDF Paris | Discovery, Drugs Key words: Protein interactions, Condyloma, Anti-viral Clients: Prescribers | Spin-off | Managing Dir.: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset] Sc.Dir.: Gauthier (Jean-Michel) [Ph.D. Molecular Biology, ex-Hybrigenics, Servier, Glaxo Wellcome, INRA] Fin.Dir.: Faure (Catherine) [Sup de Co Paris, ex-Genset] BusDev: Financers: privately owned (private investors) | 3.6 | 2.6 | Cancers | Preclin |
| Ariana Pharmaceuticals Profile + www.arianapharma.com | 2003 | IDF Paris | Contract, Knowledge Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays Clients: Pharmaceutical industry, Biotechs | Spin-off | Managing Dir.: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets] Sc.Dir.: Fin.Dir.: BusDev: Financers: Institut Pasteur, privately owned | n.a. | n.a. | Data | Subcontractor |
| Atlantic Bone Screen Profile + www.atlantic-bone-screen.com | 2005 | Bretagne Nantes | Contract, Services Key words: Validation, In-vivo testing, Osteo-articular pathologies, LPRO Clients: Pharmaceutical industry, Biotechs, Chemical industry, Food industry | Personal venture | Managing Dir.: Le Bot (Ronan) [co-founder, born 1977, Pharm.D.] Sc.Dir.: Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.04 M€) | n.a. | n.a. | Inflammation | Subcontractor |
| Aureus Pharma Profile + www.aureus-pharma.com | 2000 | IDF Paris | Contract, Knowledge Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE Clients: Pharmaceutical industry, Biotechs | Start-up | Managing Dir.: Theodosiou (Jason) [born 1959, Ph.D. Organic Chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier Sc.Dir.: Petitet (François) [Pharm.D., Ph.D.] Fin.Dir.: Riot-Lamotte (Laurence) BusDev: Donlan (Mary) Financers: Bioam, AXA, FCJE (CDC), Matignon, OTC-AM | n.a. | n.a. | Data | Subcontractor |
| BioAlliance Pharma Profile + www.bioalliancepharma.com | 1997 | IDF Paris | Discovery, Drugs (also Galenic) Key words: Cancer, HIV, Opportunistic infections Clients: Prescribers | Start-up | Managing Dir.: Costantini (Dominique) [co-founder, born 1955, M.D., ex-Hoechst-Marion-Roussel] Sc.Dir.: Auclair (Christian) [Pharm.D., Ph.D., University Prof.] Avenard (Gilles) [co-founder, born 1951, M.D., ex-Hoechst-Marion-Roussel, CNTS] Fin.Dir.: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young] SalesMktg: Dupré (Florence) BusDev: Financers: 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, Public | 91.0 | 40.0 | Cancers | Launch |
| Biocortech Profile + www.biocortech.com | 2001 | IDF Paris | Discovery, Drugs Key words: Neuro-psychiatric diseases, Biomarkers, Serotonin, Glutamate Clients: Pharmaceutical industry (own development, up to clinical trials) | Spin-off | Managing Dir.: Weissmann (Dinah) [co-founder, born 1951, Pharm.D., Ph.D. Neurobiology, ex-Roussel Uclaf, CNRS] Sc.Dir.: Pujol (Jean-François) [co-founder, M.D., Ph.D., Hospital Professor, ex-Roussel Uclaf, INSERM and CNRS] Fin.Dir.: BusDev: Financers: Institut Pasteur, business angels | n.a. | n.a. | CNS | Preclin |
| BioCydex Profile + www.biocydex.com | 2002 | Aquitaine Poitiers | Contract, Services (also, Development, Drugs) Key words: Ophthalmology, Cyclodextrins Clients: Pharmaceutical industry (up to proof of concept) | Personal venture | Managing Dir.: Belgsir (Mustapha) [co-founder, born 1958, Ph.D., ex-CNRS] Sc.Dir.: Cenatiempo (Yves) [co-founder, born 1950, Prof. biochemistry (Poitiers)] Fin.Dir.: Marembaud (Olivier) [born 1952, ex-Frantour, Kelois, SNCF] BusDev: Financers: Oseo | n.a. | n.a. | Ophthamo | Incubator |
| BioMedical Diagnostics Profile + www.bmd-net.com | 1986 | IDF Marne-la-Vallée (near Paris) | Discovery, Devices Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis Clients: Pharmaceutical industry | Start-up | Managing Dir.: Magrez (Paul) [born 1958, M.D., ex-GSK, UCB, Innogenetics] Sc.Dir.: Fin.Dir.: Géricot (Laurence) [MBA, ex-Hewlett Packard] BusDev: Financers: Truffle Venture, CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Vntech, 123 Multinova | n.a. | n.a. | Allergy | Trade |
| Biométhodes Profile + www.biomethodes.com | 1997 | IDF Évry (near Paris) | Contract, Manufacturing (also Design, Drugs) Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food | Personal venture | Managing Dir.: Amsallem (Gilles) [ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio] Sc.Dir.: Delcourt (Marc) [founder, born 1970, M.D., Normale Sup] Fin.Dir.: Liju (Xavier) BusDev: Financers: CDC Innovation, CIC Capital, FCJE (CDC) | n.a. | n.a. | Haemophilia | Trade |
| Biom'up Profile + www.biomup.com | 2005 | Rhône-Alpes Lyon | Design, Molecules (also, Contract, Manufacturing) Key words: Devices, Collagen, Glycosaminoglycans, Biopolymers, Grafting, Human reconstruction Clients: Pharmaceutical industry, Cosmetic industry, Biotechs | Spin-off | Managing Dir.: Picot (Sylvain) [co-founder, born 1978, Ph.D., Insa], Sc.Dir.: Forest (Patricia) [co-founder, born 1978, Ph.D., Insa], also Oper.Dir.] Fin.Dir.: BusDev: Financers: privately owned | 0.04 | 0.04 | Collagen | Trade |
| BioProtein Technologies Profile + www.bioprotein.com | 1998 | IDF Jouy-en-Josas (near Paris) | Contract, Manufacturing Key words: Therapeutic proteins, Gene expression, Transgenic rabbits Clients: Industry, Research labs | Personal venture | Managing Dir.: Lignel (Jean) Sc.Dir.: Ripoll (Pierre-Jean) [Ph.D., ex-Aventis, Biogemma] Fin.Dir.: BusDev: Fouassier (Alexandre) [Eng. INRA] Financers: Société Générale A.M., Gilde, Creagro, Iwic, Anvar, Hazak | 5.0 | 5.0 | Multiple | Preclin |
| BioSystems International Profile + www.biosys-intl.com | 2004 | IDF Évry (near Paris) | Design, Diagnostics Key words: Biomarkers, Drug discovery improvement, Development productivity, Serum proteins Clients: Pharmaceutical industry, Biotech | Spin-off | Managing Dir.: Tirouflet (Jean-Pierre) [born 1950, ENA, ex-Rhodia (President), MEDEF, Rhône-Poulenc, Finance Ministry, Crédit National Bank Sc.Dir.: Takacs (Laszlo) [co-founder, born 1955, M.D., Ph.D., ex-Pfizer, Parke Davis, Amgen, NIH] Tech.Dir.: Guttman (András) [co-founder, Ph.D. Chemistry, ex-Beckman Coulter] Fin.Dir.: Liebaert (François) [MBA, ex-Schering, Abbott] BusDev: Liebaert (François) Financers: Société Générale | 3.0 | 3.0 | Multiple | Trade |
| BMSystems (Bio-modeling) Profile + www.bmsystems.net | 2004 | IDF Paris | Discovery, Hub Key words: Models, Proof of concept, Predictive efficacy, Validation, Spin-off Clients: Financers | Start-up | Managing Dir.: Géa (Manuel) [co-founder, born 1960, Eng. Centrale, ex-Hemispherx (CEO), Boehringer-Ingelheim, Colgate-Palmolive, McKinsey] Sc.Dir.: Iris (François) [also board chairman, born 1950, Ph.D., ex-Valigen (co-founder), Millenium] Fin.Dir.: BusDev: Financers: privately-held | n.a. | n.a. | Multiple | Proof-of-Concept |
| BT Pharma Profile + www.btpharma.com | 2001 | Midi-Pyrénées Labège (near Toulouse) | Discovery, Immunology Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections Clients: Prescribers | Personal venture | Managing Dir.: Timmerman (Ben) [founder, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia] Sc.Dir.: Préville (Xavier) [Ph.D. Life Sciences, Gercor, Sangstat] Fin.Dir.: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon] BusDev: Financers: Institut Pasteur, FAM-Midi-Pyrénées | 3.8 | 1.3 | Vaccines | Clinical |
| Cellectis Profile + www.cellectis.com | 1999 | IDF Romainville (near Paris) | Discovery, Therapy Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair Clients: Pharmaceutical Industry, Biotechs, Agro Industry, Research labs Competitors: Applied Biosystems, 454 Life Sciences, Celera | Spin-off | Managing Dir.: Choulika (André) [co-founder, born 1965, Ph.D. virology] Sc.Dir.: Pâques (Frédéric) [Ph.D. Sciences, Normale Sup (Ulm), ex-CNRS] Fin.Dir.: Le Bozec (Marc) [HEC, ex-Alfact Innovation, Arthur D. Little, BioProtein (founder)] BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO] Financers: Kaminvest, BankInvest, AGF PE, Odyssée, Edmond de Rothschild, Public | 38.6 | 21.2 | Genome | Preclin |
| Cellial Technologies Profile + www.cellial.com | 2001 | North-Picardie Lens | Contract, Research Key words: CNS research optimization, In vitro cell culture Clients: Pharmaceutical industry, Biotechs, Academic labs | Personal venture | Managing Dir.: Wendzinski (Yves) [Eng. ISEN] Sc.Dir.: Berezowski (Vincent) [Ph.D.] Fin.Dir.: BusDev: Financers: Finorpa, Nord Innovation, Innovam | n.a. | n.a. | Multiple | Subcontractor |
| CellVax Profile + www.cellvax-pharma.com | 2001 | IDF Évry (near Paris) | Contract, Services Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II) | Personal venture | Managing Dir.: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology] Sc.Dir.: Wei (Ming) Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.04 M€) | n.a. | n.a. | Cancers | Subcontractor |
| CellVir Profile + www.cellvir.com | 2006 | IDF Évry (near Paris) | Discovery, Drugs Key words: Anti-retrovirals, AIDS, HCV, SARS, Avian Flu Clients: Prescribers | Personal venture | Managing Dir.: Courtney (Michael) [Scottish, Ph.D., ex-Aptanomics, Noxxon, Trangene (CSO)] Sc.Dir.: Benarous (Richard) [co-founder, born 1941, M.D., Ph.D., ex-Hybrigenics (co-founder), Cytomics (co-founder)] Fin.Dir.: BusDev: Platford (Richard) [Master Mechanical Sciences (Cambridge), MBA (LBS), ex-PricewaterhouseCoopers] Financers: OSEO, ANRS, ANR, Genopole 1er Jour and INSERM Transfert | 2.0 | 2.0 | Virus | Incub |
| Cerenis Therapeutics Profile + www.cerenis.com | 2005 | Midi-Pyrénées Labège (near Toulouse) | Discovery, Drugs Key words: HDL therapy, Atherosclerosis, Cardiovasculars Clients: Prescribers | Personal venture | Managing Dir.: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier] Operations Dir.: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo] Sc.Dir.: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer] Fin.Dir.: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers] BusDev: Zhu (Larry) [Ph.D., MBA, ex-Esperion Therapeutics (Pfizer)] Financers: Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures | 67.0 | 42.0 | Cardiovasc | Clinical |
| Cezanne Profile + www.cezanne.fr | 2000 | PACA Nîmes | Development, Devices Key words: Immunochemistry analysis, Kryptor analyser, Fluorescence detection, Trace technology, Automatic instruments, Reagents Clients: | Personal venture | Managing Dir.: Bois (Emmanuel) [co-founder, born 1960] Sc.Dir.: Bois (Emmanuel) Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Multiple | Trade |
| CliniGenetics Profile + www.clinigenetics.com | 2000 | PACA Nîmes | Discovery, Drugs Key words: Atherothrombosis, Atherix pig model, Alive bio-informatics Clients: Prescribers | Personal venture | Managing Dir.: Falco (Jean-Louis) [born 1949, DEA Mkg-Finance Dauphine, ex-Schneider, Aurex (own consulting company)] Sc.Dir.: Marguerie de Rotrou (Gérard) [born 1940, Ph.D., ex-Inserm, CEA, University Professor in Functional Genomics] Fin.Dir.: BusDev: Financers: BankInvest | n.a. | n.a. | Cardiovasc | Preclin |
| Covalab Profile + www.covalab.com | 1995 | Rhône-Alpes Villeurbanne (near Lyon) | Design, Drugs (also Design, Diagnostics) Key words: Immunochemistry, MABs, Polyclonal antibodies Clients: Research labs | Personal venture | Managing Dir.: El Alaoui (Saïd) [born 1955] & Thomas (Vincent) [born 1957] Sc.Dir.: Fin.Dir.: BusDev: Financers: privately owned (capital 2007 = 0.24 M€) | n.a. | n.a. | Multiple | Trade |
| Cytheris Profile + www.cytheris.com | 1999 | IDF Issy-les-Moulineaux (near Paris) | Discovery, Immunology Key words: Immune modulation, cancer, HIV, HCV, Recombinant interleukin Clients: Prescribers | Personal venture | Managing Dir.: Morre (Michel) [founder, born 1946, Vet.D., ex-Sanofi-Aventis, Pierre Fabre, M.I.T.] Sc.Dir.: Fin.Dir.: Vannier (Bertrand) BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma] Financers: Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion (capital 2006 = 52.5 M€) | 31.0 | 24.0 | Cancers | Clinical |
| Cytomics Profile + www.cytomics.fr | 2000 | IDF Orsay (near Paris) | Discovery, Drugs Key words: Ubiquitin ligases, UbiScreen, High-throughput Screening, Cancer, Nosocomial Fungal Infections Clients: Prescribers | Start-up | Managing Dir.: Cambou (Bernard) [born 1955, MBA (Essec), ex-StageMark (co-founder), Aventis-Principia, HGS, MIT] Sc.Dir.: Hercend (Thierry) [born 1952, oncologist] Fin.Dir.: Martin (Erwan) [Sup de Co (Toulouse), MBA, ex-Syndex] BusDev: Financers: Société Générale A.M., Edmond de Rotschild I.P., Truffle Venture | 13.0 | 10.0 | Cancers | Preclin |
| DBV Technologies Profile + www.dbv-technologies.com | 2002 | IDF Boulogne Billancourt (near Paris) | Discovery, Diagnostics Key words: Allergies, Electrostatic patch, Diallertest, Viaskin Clients: Pharmaceutical industry, Food industry, Cosmetics | Start-up | Managing Dir.: Biry (Jean-François) [born 1955, ex-Cider Santé (President)] Sc.Dir.: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics] & Dupont (Bertrand) [Ensam] Fin.Dir.: Reinaud (Florian) [M.D. (London), ex-Apax Partners, Citigroup] BusDev: Chan (Hing Kin) Financers: Cap Décisif, Créagro, Sofinnova Partners, Apax Partners | 13.3 | 12.3 | Allergy | Trade |
| Diatos Profile + www.diatos.com | 1999 | IDF Paris | Galenics, Drugs Key words: Drug delivery, Peptides, Tumor targeting, Cancer, Chemotherapy, Prodrugs, Liposome, Vectocell, DaunoXome Clients: Prescribers | Spin-off | Managing Dir.: Tchélingérian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder)] Sc.Dir.: Gasmi (Jamal) [M.D. Oncology, Master Sc., ex-Roche, Gustave Roussy] Fin.Dir.: SalesMktg: Cowburn (James) [Ph.D. Biochemistry, ex-Zeneus Pharma, Roche, Schering Plough] BusDev: Financers: GIMV, InterWest Partners, Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners, NIF, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), Innoven, BFF, Credit Agricole P.E. | 54.8 | 9.4 | Cancers | Trade |
| DNA Therapeutics Profile + www.dna-therapeutics.com | 2006 | IDF Évry (near Paris) | Discovery, Drugs Key words: Cancer, siDNA, DNA repair Clients: Prescribers | Personal venture | Managing Dir.: Sun (Jian Sheg) [born 1959, Ph.D.] Sc.Dir.: Sun (Jian Sheg) Fin.Dir.: BusDev: Financers: privately owned | 0.4 | 0.4 | Cancers | Preclin |
| Drugabuse Sciences Profile + www.drugabusesciences.com | 1994 | Rhône-Alpes Villeurbanne (near Lyon) | Discovery, Drugs Key words: Antagonism, Addiction, Alcoholism, Toxicomany, Cocaine, Opioids Clients: Prescribers | Start-up | Managing Dir.: Langlois (Patrick) [born 1945, ex-Aventis (Board member, Rhône Poulenc] Sc.Dir.: Fin.Dir.: BusDev: Financers: CDC Ixis, Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management | n.a. | n.a. | Addiction | Clinical |
| Dynabio Profile + www.dynabio.com | 1992 | PACA Marseille | Design, Diagnostics Key words: Stress proteins, Pancreatitis-Associated Protein (PAP), PancrePAP kit Clients: | Personal venture | Managing Dir.: Broto (Ruben) [born 1937] Sc.Dir.: Oper.Dir.: Slagel (Dean) [born 1970] Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Multiple | Preclin |
| Endotis Pharma Profile + www.endotis.com | 2003 | IDF Romainville (near Paris) | Discovery, Drugs Key words: Small-glyco drugs (SGD), Thrombosis, Cancer Clients: Prescribers | Start-up | Managing Dir.: Woller (Charles) [M.D., Ph.D. Clinical pharmacology, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo] Sc.Dir.: Petitou (Maurice) [Ph.D., ex-Sanofi] Fin.Dir.: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C] BusDev: Financers: Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners | 34.0 | 25.0 | Multiple | Preclin |
| Epixis Profile + www.epixis.com | 2003 | IDF Paris | Discovery, Immunology Key words: C-Hepatitis, Mimetic particles, Virus-like particle vaccines Clients: Pharmaceutical industry | Personal venture | Managing Dir.: Frisen (Charlotte) Sc.Dir.: Fin.Dir.: BusDev: Financers: Génopole 1er Jour | n.a. | n.a. | Virus | Preclin |
| ERYtech Pharma Profile + www.erytech.com | 2004 | Rhône-Alpes Lyon | Galenics, Drugs Key words: Encapsulation, Red blood cells, Cancer, Cleav'Ery, Oxygen'Ery, Deliv'Ery Clients: Prescribers | Personal venture | Managing Dir.: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed] Sc.Dir.: Godfrain (Yann) & (medical) Liens (David) [M.D., ex-Merck (KgaA) Fin.Dir.: Dujardin (Philippe) [Master in Finance, ex-Atari, Suez-Lyonnaise des Eaux] BusDev: Goineau (Pierre-Olivier) [co-founder, ex-KPMG] Financers: AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys | 13.0 | 12.0 | Cancers | Clinical |
| Exonhit Profile + www.exonhit.com | 1997 | IDF Paris | Discovery, Diagnostics (also Drugs) Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer Clients: Pharmaceutical industry (own development up to phase II) | Personal venture | Managing Dir.: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhöne Poulenc Rorer] Sc.Dir.: Pando (Matthew) [Ph.D.] and Jaskowiak (John R.) [ex-Hewlett Packard, Agilent, Affymetrix] Fin.Dir.: Rousseau (Philippe) [HEC, ex-Valigen, Genset, Mars, Paribas] BusDev: Vickery (William) [MBA, ex-Roche Pharma] Financers: CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Public | 84.0 | 3.4 | Genome | Clinical |
| Faust Pharmaceuticals Profile + www.faustpharma.com | 2001 | Alsace Illkirch Graffenstaden (near Strasbourg) | Discovery, Drugs Key words: Neurological disorders, Neurotransmitter modulation, GPCR Clients: Prescribers | Personal venture | Managing Dir.: Seoh (Thomas) [born 1957, J.D. (Harvard), ex-Guilford Pharmaceuticals, ICN (today Valeant)] Sc.Dir.: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor] & (medical) Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo] Fin.Dir.: BusDev: Financers: Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE | 27.2 | 8.2 | CNS | Clinical |
| Flamel Technologies Profile + www.flamel.com | 1990 | Rhône-Alpes Venissieux (near Lyon) | Galenics, Drugs (also, Devices) Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry | Start-up | Managing Dir.: Willard (Stephen H.) [born 1960, ex-Biovail, Crédit Suisse, Gibson-Dunn-Crutch, Shearman & Sterling] Sc.Dir.: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] Oper.Dir.: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé] Fin.Dir.: Crouzet (Sian) [ex-McCormik, Ernst & Young] BusDev: Francis (Andrew) [Pharm.D., ex-Skyepharma] Financers: Public (Nasdaq) | n.a. | n.a. | Multiple | Trade |
| Fluofarma Profile + www.fluofarma.com | 2005 | Aquitaine Bordeaux | Contract, Services Key words: High Content Screening (HCS), Automated flow cytometry Clients: Pharmaceutical industry, Biotech | Spin-off | Managing Dir.: Pin (Jean-Baptiste) [founder, born 1974, Ernst & Young Biotechnology] Sc.Dir.: Depierre (Gaëlle) [ex-Urogene] Fin.Dir.: BusDev: Mahfoudi (Abderrahim) [ex-Aventis, Nautilus Biotech, Intergragen, Cerep, Guerbet, Inserm-Transfert] Financers: privately owned (capital 2006 = 0.24 M€) | n.a. | n.a. | Multiple | Subcontractor |
| Fovea Pharmaceuticals Profile + www.fovea-pharma.com | 2005 | IDF Paris | Discovery, Drugs Key words: Ophthalmology, Allergy conjunctivitis, Mavular edema, Retinitis pigmentosa Clients: Pharmaceutical industry (own development, up to preclinical) | Start-up | Managing Dir.: Gilly (Bernard) [born 1957, Ph.D. bioeconomy, ex-Sofinnova, Trangene (CEO), Pasteur-Mérieux-Connaught] Sc.Dir.: Fin.Dir.: Davitian (Bernard) [born 1960, MBA, ex-Neurotech (CEO), Transgene, Pasteur-Mérieux] Oper.Dir.: Bélichard (Pierre) [ex-Urogene, Ethypharm, Fournier] BusDev: Sternberg (Garry) [M.D., MBA, ex-Eyetech, BMS] Financers: Sofinnova Partners, CAPE, Abingsworth Mangement, The Wellcome Trust, GIMV | 50.5 | 30.0 | Ophthalmo | Preclin |
| GemacBio Profile + www.gemacbio.com | 2001 | Aquitaine Cenon (near Bordeaux) | Contract, Manufacturing (also, Development, Drugs) Key words: Antibodies, Customization, CNS disorders, Auto-immune diseases Clients: Distributors, Pharmaceutical indsutry, Biotech, Research labs | Personal venture | Managing Dir.: Geffard (Michel) [M.D., ex-Inserm] Sc.Dir.: Geffard (Michel) Fin.Dir.: BusDev: Financers: IRDI, ACI, SOCRI, Oséo/Anvar, business angels | n.a. | n.a. | CNS | Trade |
| Genepep Profile + www.genepep.com | 2003 | Midi-Pyrénées Prades le Lez (near Montpellier) | Discovery, Drugs Key words: Peptides, Transcriptomes, Bio-informatics softwares Clients: Pharmaceutical industry (own development up to proof of concept) | Personal venture | Managing Dir.: Puget (Karine) [co-founder, born 1970, Ph.D., ex-CNRS] Sc.Dir.: Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Multiple | Preclin |
| Genewave Profile + www.genewave.com | 2001 | IDF Palaiseau (near Paris) | Design, Devices Key words: Automated real-time micro-array, Hybridization imaging systems, Low-cost micro-array readers Clients: Research labs, Biotech, Other Institutions, OEM markets | Personal venture | Managing Dir.: Desforges (François X.) [Ph.D. Electronics, ex-Photonetics] and (CEO) Choumane (Houtaï) [Ph.D. Optics] Sc.Dir.: Weisbuch (Claude) [co-founder, born 1945, Ph.D. physics, Normale Sup, CNRS, University Professor (USA), ex-Bell Laboratories, Saint-Gobain, Thomson-CSF] and Cerovic (Gordana) [Ph.D., ex-ValiGen] Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Multiple | Trade |
| Genfit Profile + www.genfit.com | 1999 | North-Picardie Lille | Discovery, Drugs Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes Clients: | Start-up | Managing Dir.: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M] Sc.Dir.: Hum (Dean W.) [Ph.D. biochemistry] Fin.Dir.: Huitorel (Nathalie) [ex-MS Composites, Finuchem] BusDev: Financers: Finorpa, Nord Cration, BP Création, Public | n.a. | 15.0 | Cardiovasc | Clinical |
| GenOdyssee Profile + www.genodyssee.com | 1999 | IDF Évry (near Paris) | Galenics, Drugs Key words: Low-burn model, Interferon, HCV Clients: Prescribers | Personal venture | Managing Dir.: Escary (Jean-Louis) [founder, born 1964, Ph.D. molecular biology, ex-UCLA, CNG, ] Sc.Dir.: Fin.Dir.: BusDev: Financers: Matignon I.F., with Edmond de Rotschild Fin., Société Générale A.M., George Cohen | n.a. | n.a. | Virus | Preclin |
| GenoSafe Profile + www.genosafe.com | 2003 | IDF Évry (near Paris) | Contract, Service Key words: Bio-therapeutics, Drug evaluation Clients: Pharmaceutical industry, Biotechs, Research labs | Start-up | Managing Dir.: Masquelier (Anne-Marie) [born 1953, M.D. endocrinology, also Managing Dir. Genethon, ex-MDS Pharma Services, Omnicare] Sc.Dir.: Audit (Muriel) [Ph.D. Biology, ex-Genethon] Fin.Dir.: BusDev: Zuliani (Vincent) [Master Microbiology, ex-Genethon] Financers: AII (seed) | 3.5 | 3.5 | Multiple | Subcontractor |
| GenoScience Pharma Profile + www.genosciencepharma.com | 2001 | PACA Marseille | Discovery, Drugs (also, Design, Drugs) Key words: Antivirals, Predict-Search, GenMol, Protease inhibitor, HCV Clients: Pharmaceutical industry | Personal venture | Managing Dir.: (interim) Halfon (Philippe) [founder, born 1960, M.D., Ph.D., Alphabio (CEO)] Sc.Dir.: Benech (Philippe) [Ph.D., ex-CNRS] Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Virus | Preclin |
| Genoscreen Profile + www.genoscreen.fr | 2000 | North-Picardie Lille | Contract, Research Key words: Genotyping, Sequencing, Mutation detection, Microbial identification Clients: Pharmaceutical industry, Biotechs | Spin-off | Managing Dir.: Tordeux (André) [born 1947] Sc.Dir.: Fin.Dir.: BusDev: Financers: | n.a. | n.a. | Genome | Subcontractor |
| GenOway Profile + www.genoway.com | 1999 | Rhône-Alpes Lyon | Contract, Research Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests Clients: Research labs | Spin-off | Managing Dir.: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA] Sc.Dir.: Fin.Dir.: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome] BusDev: Thiam (Kader) Financers: Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public | 10.8 | 1.1 | Genome | Subcontractor |
| Helios Biosciences Profile + www.helios-biosciences.com | 2002 | IDF Créteil (near Paris) | Discovery, Targets Key words: Tissue expression, InSitu Hybridization, Biomarkers, Prostate cancer, Epilepsy, SIMPathway Clients: Research labs | Academic | Managing Dir.: Dumas (Jean-Baptiste) [founder, born 1958, Ph.D., ex-Genset, Genethon] Sc.Dir.: Dumas (Syvie) [Ph.D., Normale Sup, ex-CNRS] Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.15 M€) | n.a. | n.a. | Cancers | Preclin |
| Hybrigenics Profile + www.hybrigenics.com | 1997 | IDF Paris | Discovery, Drugs (also, Services, Research) Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs) Clients: Prescribers | Academic | Managing Dir.: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)] Sc.Dir.: Daviet (Laurent) [Ph.D. molecular biology] Oper.Dir.: Petitville (Didier) [ex-Institut Pasteur] Fin.Dir.: Cohen, Eric [MBA (LBS), ex-Teva, Mazars, Radio BFM] BusDev: Financers: Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public | n.a. | 6.2 | Cancers | Preclin |
| Hyphen BioMed Profile + www.hyphen-biomed.com | 1999 | IDF Neuville-sur-Oise (near Paris) | Discovery, Diagnostics Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest Clients: Research labs | Personal venture | Managing Dir.: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)] Sc.Dir.: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago] Fin.Dir.: BusDev (& sales): Penissard (Véronique) Financers: privately owned, IDF Développement, Banque Populaire | n.a. | n.a. | Cardiovasc | Trade |
| Imagene Profile + www.imagene.fr | 1998 | Aquitaine Pessac (near Bordeaux) | Contract, Manufacturing Key words: DNA-conservation, Encapsulation, Extraction Clients: Research labs | Personal venture | Managing Dir.: Tuffet (Sophie) Sc.Dir.: Indus.Dir.: Palluet (Jean-Noël) Fin.Dir.: BusDev: Financers: OTC A.M. and Aquitaine Création Investissement | n.a. | 2.0 | Genome | Trade |
| ImmunId Profile + www.immunid.com | 2005 | Rhône-Alpes Grenoble | Contract, Research Key words: Immunology analysis, T & B cell repertoire, Genomic DNA, Infectious diseases, Blood cancer, ImmunTracker, ImmunIg Clients: Research labs, Hospitals, Pharmaceutical industry | Personal venture | Managing Dir.: Pasqual (Nicolas) [co-founder, born 1977, Ph.D. molecular biology, ex-CEA] Sc.Dir.: Oper.Dir.: Weisbuch (Sébastien) [Ph.D. nonobiology, ex-CEA] Fin.Dir.: BusDev: Plantier (Nadia) Financers: privately owned (capital 2006 = 0.053 M€) | n.a. | n.a. | Multiple | Trade |
| Immutep Profile + www.immutep.com | 2001 | IDF Orsay (near Paris) | Discovery, Drugs Key words: Cancer, Chronic Infectious Diseases, T cell immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein Clients: Prescribers | Spin-off | Managing Dir.: Hawken (John B.) [born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell] Sc.Dir.: Triebel (Frédéric) [born 1954, M.D., ex-Inserm] Fin.Dir.: BusDev: Financers: Innoven Partenaires, H2i | 6.7 | 2.5 | Cancers | Clinical |
| Imstar Profile + www.imstar.fr | 1985 | IDF Paris | Contract, Service Key words: Microscopic imaging, Cell screening, Systems, Instruments, High throughput, Pathfinder Clients: Research labs | Spin-off | Managing Dir.: Soussaline (Françoise) [born 1945] Sc.Dir.: Soussaline (Françoise) Fin.Dir.: BusDev: Financers: privately owned | n.a. | n.a. | Studies | Subcontractor |
| In-Cell-Art Profile + www.incellart.com | 2005 | Bretagne Nantes | Design, Delivery (also Discovery, Drugs) Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies Clients: Pharmaceutical industry, Biotechs, Academic labs | Personal venture | Managing Dir.: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth] Sc.Dir.: Pitard (Bruno) [co-founder, ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm] Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.05 M€) | 0.45 | 0.25 | Multiple | Preclin |
| Indicia Biotechnology Profile + www.indicia.fr | 1998 | Rhône-Alpes Lyon | Contract, Research Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods Clients: Pharmaceutical industry, Diagnostics industry | Personal venture | Managing Dir.: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa] Sc.Dir.: SalesMktg: Panier (Elodie) Fin.Dir.: BusDev: Financers: privately owned | n.a. | n.a. | Studies | Subcontractor |
| Innate Pharma Profile + www.innate-pharma.com | 1999 | PACA Marseille | Discovery, Drugs Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer Clients: Prescribers | Start-up | Managing Dir.: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter] Sc.Dir.: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter] Fin.Dir.: Boissel (Stéphane) [ex-Lazard] BusDev: Shah (Hemansu) [Ph.D., MBA, ex-GPC Biotech, BMS, J&J] Financers: Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public | 102.2 | 33.7 | Cancers | Clinical |
| IntegraGen Profile + www.integragen.com | 2000 | IDF Évry (near Paris) | Discovery, Diagnostics Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP Clients: Prescribers | Spin-off | Managing Dir.: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba] Sc.Dir.: Hager (Jörg) [co-founder, Ph.D., ex-Pasteur Lille] I.T.Dir: Gesnouin (Philippe) [co-founder, ex-Xeotron, Lexicon Genetics] Fin.Dir.: Court (Patrick) [born 1958, Sup de Co (Paris), ISG] SalesMktg: Gottlieb (Robert) [MBA, ex-Roche Diagnostic, Becton Dickinson, G.E., Abbott] BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza] Financers: CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM | 16.3 | 2.0 | Cardiovasc | Clinical |
| Ipsogen Profile + www.ipsogen.com | 1999 | PACA Marseille | Discovery, Diagnostics Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia Clients: Research labs, Prescribers | Personal venture | Managing Dir.: Fert (Vincent) [co-founder, born 1959, Ms. immunolgy, ex-Immunotech] Sc.Dir.: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS] Oper.Dir.: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter] Fin.Dir.: Piot (Stanislas) [ex-Natixis, Crédit Lyonnais, Oddo, Worms] BusDev: Financers: Samenar (Caisse d'Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public | 21.8 | 11.8 | Cancers | Trade |
| Ivagen Profile + www.ivagen.com | 2002 | PACA Bernis (near Nîmes) | Discovery, Diagnostics Key words: Immuno-hematology, Medical devices, HIV, H5N1 Clients: | Personal venture | Managing Dir.: Skorski (Gilbert) [born 1955] Sc.Dir.: Fin.Dir.: BusDev: Financers: Matignon I.G., OTC Asset Management (33%) | n.a. | n.a. | Virus | Trade |
| LibraGen Profile + www.libragen.com | 2001 | Midi-Pyrénées Toulouse | Design, Development (also, Identification, Drugs) Key words: Bioprocesses, Enzymes, Bio-catalysis, Meta-Dna libraries, Small molecules identification, Micro-organisms Clients: Pharmaceutical industry, Chemical industry, Cosmetics industry | Personal venture | Managing Dir.: Nalin (Renaud) [born 1967, Ph.D., ex-CRO] Sc.Dir.: Lefèvre (Fabrice) [Ph.D., Insa, ex-Protéus] Fin.Dir.: BusDev: Financers: Bioam, Galia Gestion | n.a. | n.a. | Studies | Proof-of-Concept |
| Mapreg Profile + www.mapreg.com | 2000 | IDF Le Kremlin-Bicêtre (near Paris) | Discovery, Drugs Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury Clients: Pharmaceutical industry (own development up to phase II included) | Academic | Managing Dir.: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.] Sc.Dir.: Robel (Paul) [M.D.] Oper.Dir.: Le Bouteiller (Denis) [Eng. Centrale (Lyon), Ms. Sciences, MBA] Fin.Dir.: BusDev: Financers: | n.a. | n.a. | CNS | Preclin |
| MAT Biopharma Profile + www.matbiopharma.fr | 1999 | IDF Évry (near Paris) | Discovery, Drugs Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis Clients: Pharmaceutical industry (own development up to phase II included) | Personal venture | Managing Dir.: Kadouche (Jean) [co-founder, born 1945, M.D., Pharm.D., ex-Merck US, Sangstat, Ortho-J&J] Sc.Dir.: Boumsell (Laurence) Fin.Dir.: Barbelanne (Michel) [M.Sc.] BusDev: Gomez (Frédéric) [Pharm.D., ex-BNP] Financers: Génopole 1er Jour, IxCore, Anvar | 5.8 | 5.8 | Cancers | Preclin |
| Medesis Pharma Profile + www.medesispharma.com | 2003 | IDF Paris | Discovery, Drugs Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome Clients: | Personal venture | Managing Dir.: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)] Sc.Dir.: Oper.Dir.: Cudenec (Claude-Alain) [Ph.D., ex-Servier, Pierre Fabre] Fin.Dir.: BusDev: Financers: privately owned | n.a. | n.a. | Multiple | Preclin |
| Mellitech Profile + www.mellitech.com | 2005 | Rhône-Alpes Grenoble | Discovery, Drugs (also Diagnostics) Key words: Type 2 diabetes, Zinc transporter protein Clients: | Spin-off | Managing Dir.: Barth (Philippe) [born 1952, M.D., MBA, ex-Siparex, Merck KGaA, Bayer, Wellcome, Guerbet] Sc.Dir.: Chimienti (Fabrice) [Ph.D.] Fin.Dir.: BusDev: de Boysson (Yann) [co-founder] Financers: privately owned (capital 2006 = 0.08 M€) | 0.5 | 0.5 | Cardiovasc | Preclin |
| Meristem Therapeutics Profile + www.meristem-therapeutics.com | 1997 | Centre Clermont-Ferrand | Design, Drugs (also Discovery, Drugs) Key words: Therapeutic Proteins, Gene technology, Plants, MABs, Manufacturing, Processing, Third Parties, Merispase Clients: Pharmaceutical industry, Biotechs | Start-up | Managing Dir.: Rohmer (Jean-Paul) [born 1947, Ph.D. Management, Dauphine, ex-Eli Lilly, Stallergènes (CEO)] Sc.Dir.: Burtin (Daniel) [Ph.D. Biochemistry, ex-INRA] Oper.Dir.: Boisgard (Catherine) [ex-Human Resources] Fin.Dir.: BusDev: Financers: Limagrain (Unigrains), BNP, Tethys, 3i, Sofipar, Sofimac, AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF | n.a. | n.a. | Multiple | Trade |
| MicroBioChips Profile + www.microbiochips.com | 2006 | IDF Evreux Paris | Design, Diagnostics Key words: Biochip, Micro-arrays, Cytokine, Anti-body, MicroVigene Clients: Pharmaceutical industry, Agro industry, Cosmetics industry | Personal venture | Managing Dir.: Saulot (Vincent) [co-founder, born 1975, Ph.D., Eng. Insa, ex-BioMedical Diagnostic, Chiron] Sc.Dir.: Malingue (Frédéric) [ex-Biorad] Fin.Dir.: BusDev: Azadian (Pascal) [co-founder, ex-other biotechs] Financers: privately owned (capital 2006 = 0.04 M€) | 0.3 | 0.3 | Multiple | Trade |
| MilleGen Profile + www.millegen.com | 1999 | Midi-Pyrénées Labège (near Toulouse) | Contract, Manufacturing Key words: Directed Molecular Evolution (DME), MutaGen, Mutascreen, Gene cloning, High throughput screening, Antibodies, Peptides Clients: Pharmaceutical industry, Research labs, Biotechs | Personal venture | Managing Dir.: Kharrat (Abdel Hakim) [born 1961, Ph.D. biology] Sc.Dir.: Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.07 M€) | 0.6 | 0.6 | Multiple | Subcontractor |
| MitoProd Profile + www.mitoprod.com | 2004 | Aquitaine Bordeaux | Contract, Manufacturing Key words: RNA-factory, Mitochondrial DNA, Yeast, Custom nucleotides, RNA Genix Clients: Pharmaceutical industry | Personal venture | Managing Dir.: Plane (Guillaume) [born 1978] Sc.Dir.: Fin.Dir.: BusDev: Financers: Aquitaine Création Innovation, Business angels, privately owned | 2.2 | 1.6 | Multiple | Trade |
| Murigenetics Profile + www.murigenetics.com | 2005 | PACA Marseille | Discovery, Drugs Key words: Genetic diseases, Charcot, Hereditary neuropathy, Genetic mental disorders Clients: Prescribers | Personal venture | Managing Dir.: Le Boulay (Morgane) [born 1981, Eng. Centrale, ex-BCG] Sc.Dir.: Oper.Dir.: Pinachyan (Karen) [M.D., Ms. management] Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.04 M€) | n.a. | n.a. | Genome | Preclin |
| Mutabilis Profile + www.mutabilis.fr | 2001 | IDF Romainville (near Paris) | Discovery, Drugs Key words: Antibacterials, Severe infections, Nosocomial diseases Clients: Prescribers | Spin-off | Managing Dir.: Fischer (Stephan) [born 1961, Ms. chemistry, ex-Lorentis (CEO), Capsant, Roche] Sc.Dir.: Escaich (Sonia) [Ph.D., ex-Sandoz, Rhône Poulenc] Fin.Dir.: BusDev: Financers: Bioam, AXA P.E., Inserm-Transfert, Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.) | 10.2 | 8.0 | Infections | Clinical |
| Myosix Profile + www.myosix.com | 2000 | IDF Paris | Discovery, Immunology Key words: Cell Transplantation, Muscle cells, Myopathies, Saint-Louis Clients: Hospitals | Academic | Managing Dir.: Turner (Frederic) [Genzyme] Sc.Dir.: Dalle (Bruno) [Pharm.D.] Fin.Dir.: BusDev: Ritsou (Elena) Financers: privately owned (51%), Genzyme (49%) | n.a. | n.a. | Muscle | Preclin |
| NanoBiotix Profile + www.nanobiotix.com | 2003 | IDF Paris | Design, Drugs Key words: Nanoparticles, Cancer, NonoXray Clients: | Personal venture | Managing Dir.: Levy (Laurent) [co-founder, born 1971, Ph.D., ex-Rhône Poulenc, Rhodia, Guerbet, Altran] Sc.Dir.: Oper.Dir.: Boussaha (Kader) [co-founder, born 1973] Fin.Dir.: BusDev: Financers: Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management | 8.0 | 7.0 | Preclin | Preclin |
| Nautilus Biotech Profile + www.nautilusbiotech.com | 2000 | IDF Évry (near Paris) | Galenics, Drugs Key words: Therapeutic Proteins, Slow-released HGH, Interferon beta Clients: Prescribers | Start-up | Managing Dir.: Parkinson (Philip) [born 1956, MBA, ex-Pfizer France] Sc.Dir.: Drittanti (Lila) [ex-Genethon] Fin.Dir.: BusDev: Vega (Manuel) [co-founder, born 1960, Ph.D., ex-Microgen, Genethon] Financers: Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. | 25.3 | 8.4 | Multiple | Prereg |
| Neorphys Profile + www.neorphys.com | 2005 | PACA Nîmes | Discovery, Drugs Key words: Female desire dysfunction, Nausea-free acute pain, Morphine derivatives, Analgesics Clients: Prescribers | Personal venture | Managing Dir.: Lahana (Roger) [co-founder, born 1954, ex-Syntem] Sc.Dir.: Oper.Dir.: Larbouret (Karine) [co-founder, ex-Syntem] Fin.Dir.: BusDev: Financers: Soridec, Inserm-Transfert | 0.3 | 0.3 | Multiple | Preclin |
| Neovacs Profile + www.neovacs.com | 1993 | IDF Paris | Discovery, Immunology Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids Clients: Prescribers | Spin-off | Managing Dir.: Fanneau de la Horie (Guy-Charles) [Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough] Sc.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur] Fin.Dir.: BusDev: Financers: Truffle Ventures, Europe Innovation, Debiopharm, Novartis | n.a. | n.a. | Cancers | Clinical |
| Neuronax Profile + www.neuronax.com | 2003 | Centre Saint Beauzire (near Clermont-Ferrand) | Discovery, Drugs (also Contract, Services) Key words: Neural repair, Parkinson disease, Ataxy, NX peptides Clients: Pharmaceutical industry (out-licensing after proof-of-concept) | Spin-off | Managing Dir.: Gobron (Stéphane) [born 1968] Sc.Dir.: Gobron (Stéphane) Fin.Dir.: BusDev: Financers: privately owned (capital 200- = 0.04 M€) | n.a. | n.a. | CNS | Proof-of-Concept |
| NicOx Profile + www.nicox.com | 1996 | PACA Nice | Galenics, Drugs Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis Clients: Prescribers | Start-up | Managing Dir.: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco] Sc.Dir.: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz] Fin.Dir.: Castaldi (Eric) BusDev: Sharma (Sanjiv) SalesMktg: Sharma (Sanjiv) Financers: Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Public | 230 (over) | 130 | Multiple | Pre-reg |
| Nokad Profile + www.nokad-technology.com | 2004 | IDF Évry (near Paris) | Discovery, Targets Key words: Secreted proteins inactivation, Functional knock-out, Protein vaccination, Mammals Clients: Pharmaceutical industry, Research labs | Personal venture | Managing Dir.: Abina (Amine) [co-founder, M.D. immunology, Ph.D., ex-AFSSAPS] Sc.Dir.: Erard (François) [Ph.D., University Professor, ex-Novartis] Fin.Dir.: Yachou (Abdelkader) [Ph.D. molecular biology, MBA] BusDev: Financers: Cap Décisif and Genopole 1er Jour, privately owned | n.a. | n.a. | Studies | Trade |
| Novagali Profile + www.novagali.com | 2000 | IDF Évry (near Paris) | Galenics, Drugs Key words: Ophthalmology, Conjunctivitis, Glaucoma, Retinopathies, Novasorb, Eyeject Clients: Pharmaceutical industry (own development up to registration) | Start-up | Managing Dir.: Martinez (Jérôme) [born 1960, Pharm.D., Pharmaco-economics, MBA, ex-Ethypharm, Lavipharm, Roussel Uclaf, Alliance Santé] Sc.Dir.: Lambert (Grégory) [Ph.D.] Fin.Dir.: Garcia (Philippe) [born 1964, Ms. Finance, CPA, ex-Floreane, Goodrich, EuroCave, Deloitte & Touche] BusDev: Garrigue (Jean-Sébastien) [Pharm.D., MBA, ex-Batelle] Financers: CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E., Edmond de Rothschild I.P., Siparex | 44.0 | 26.0 | Ophthalmo | Launch |
| Novexel Profile + www.novexel.com | 2004 | IDF Romainville (near Paris) | Discovery, Drugs Key words: Anti-infectives, Anti-fungals Clients: Prescribers | Spin-off | Managing Dir.: Buchanan (Iain) [born 1952, ex-Vertex, J&J, Biogen] Sc.Dir.: Sable (Carole A.) [M.D., ex-M.S.D.] Fin.Dir.: Waldron (Gordon) [ex-Syntem, Texas Instruments, Spie Batignolles] BusDev: Mangasarian (Aram) [Ph.D., MBA, ex-ExonHit Therapeutics] Financers: Sanofi-Aventis, Atlas Venture, Sofinnova, 3i, Abingworth, Novo | 90.0 | 50.0 | Infections | Clinical |
| NovoCIB Profile + www.novocib.com | 2005 | Rhône-Alpes Lyon | Contract, Manufacturing Key words: Nucleotides, Antivirals, HCV, Enzymes, Previce platform Clients: Pharmaceutical Industry, Biotechs | Personal venture | Managing Dir.: Godard (Nicolas) [Ms. microbiology (INA), MBA] Sc.Dir.: Balakireva (Larissa) [founder, born 1966, Ph.D. Cell Biology, ex-IBS] Fin.Dir.: BusDev: Financers: privately owned (capital 2006 = 0.04 M€) | n.a. | n.a. | Virus | Subcontractor |
| Novotec Profile + www.novotec-labs.com | 1997 | Rhône-Alpes Lyon | Contract, Manufacturing Key words: Antibodies, Extra cellular matrix (ECM) Clients: Pharmaceutical industry, Biotechs, Research labs | Spin-off | Managing Dir.: Guerret (Sylviane) [born 1950] Sc.Dir.: Hartmann (Daniel) Fin.Dir.: BusDev: Prulières (Franck) Financers: privately owned (capital 2006 = 0.065 M€) | n.a. | n.a. | Multiple | Subcontractor |
| ObeTherapy Profile + www.obetherapy.com | 2000 | IDF Évry (near Paris) |